From the high desert and the great American Southwest, Art welcomes Bob Guccione, publisher and editor-in-chief of Penthouse magazine. Bob discusses the evolution of Penthouse, noting its bold steps and changes to reflect the new morality. He describes the magazine’s positioning between Hustler and Playboy, and recounts its origins in England, inspired by the American Playboy. Bob shares the challenges he faced in finding financial backing, ultimately leading to Penthouse’s success.
Art and Bob delve into the film “The People vs. Larry Flynt,” discussing its portrayal of Larry Flynt and the differences between Flynt’s battles and those fought by Penthouse and Playboy. Bob explains the impact of the internet on Penthouse, highlighting its early adoption of online platforms and the challenges of regulating online content. He emphasizes the impracticality of censoring the internet due to its international nature and the ambiguity surrounding the term “indecent.”
The conversation shifts to Bob’s personal life, particularly his wife Kathy’s battle with late-stage breast cancer. Bob recounts the rapid progression of her illness, from a clear mammogram to widespread metastasis within six weeks. He describes the emotional toll of her diagnosis and the impact on their lives.
Two years ago, Bob Guccione’s wife, Kathy, was diagnosed with late-stage four breast cancer and given six weeks to live. Refusing traditional treatments like chemotherapy, radiation, and surgery, Kathy chose not to introduce more toxins into her body. Instead, Bob turned to hydrazine sulfate, a cancer therapy they had been covering in Penthouse for 18 years. Hydrazine sulfate, originally an industrial cleaner and component in rocket fuel, had medicinal value and was listed on the pharmacopeia for 55 years. Dr. Joe Gold from Syracuse Cancer Research Center developed it to prevent cachexia, the late stage of cancer where the body begins to wither away.
Bob recounted their collaboration with the Soviet Academy of Sciences, which had been conducting human trials with hydrazine sulfate for 17 years due to its affordability. The main issue in the U.S. was that its low cost made it unprofitable for pharmaceutical companies, leading to resistance from institutions like the National Cancer Institute. Despite the low cost of $150 a year for hydrazine sulfate treatment, compared to $30,000 to $40,000 for conventional cancer treatments, the government showed little interest.
Kathy’s choice to use hydrazine sulfate led to a remarkable recovery. From a prognosis of three to six weeks, she has been in complete remission for almost a year, healthier and weighing more than before.
Bob explains that hydrazine sulfate, while primarily treating cachexia, also has tumor-shrinking effects, making it a valuable yet underutilized drug. Despite its availability, it is difficult to find doctors willing to prescribe it due to its low profitability. However, interest is growing, with 250 oncologists weekly contacting Dr. Joe Gold for guidance. Kathy’s treatment at Mount Sinai, a chemotherapy stronghold, initially faced skepticism, but her recovery has led some doctors there to reconsider. Dr. Lynn Ratner, a prominent oncologist at Mount Sinai, now has 25 patients on hydrazine sulfate, all of whom are doing well, with some showing tumor regression.
Art and Bob discuss how people can access hydrazine sulfate. Bob advises reading the September issue of Penthouse or writing to General Media for comprehensive information. He highlights the challenges in conducting large-scale trials, recounting how the National Cancer Institute (NCI) sabotaged trials at UCLA by introducing incompatible elements to patients’ treatments, leading to misleading results. Despite this, Kathy’s positive experience continues to challenge the status quo, underscoring the potential of hydrazine sulfate and the need for unbiased research.
Bob shares how their accusations against the NCI led to an investigation by the Government Accountability Office (GAO). The GAO found credible evidence that the NCI had deliberately sabotaged the trials by using incompatible substances, despite internal memos proving they knew the proper protocol. Despite the NCI’s retrospective analysis claiming these incompatibilities did not affect the trial outcomes, Bob and his team are not convinced and are seeking families of trial participants to file a class action lawsuit for what they term as genocide. Bob cites historical government misconduct, like the Tuskegee experiments, to underscore the seriousness of their claims.
Bob emphasizes the need for honest tests and government investment in alternative remedies like hydrazine sulfate. He highlights that despite billions spent on cancer research, cancer incidence rates per capita have increased. Art and Bob discuss the possible reasons for rising cancer rates, attributing it to increasing stress, overpopulation, depletion of natural resources, and consumption of artificial foods and hormone-laden meat. Bob calls for proper trials and greater awareness of alternative treatments to combat the growing cancer epidemic.
Bob and Art discuss the widespread use of artificial substances in food and the environmental contaminants contributing to health issues, including cancer. Bob argues that the increase in cancer rates is linked to stress, poor diet, and environmental factors. Art adds that societal changes and behaviors are also problematic, predicting a significant global event that will act as a wake-up call.
Bob reveals plans for a class action lawsuit against the NCI, aiming to prompt honest tests for alternative treatments like hydrazine sulfate. Despite their efforts, including discussions with congressmen and senators, the FDA’s stringent regulations and refusal to accept foreign test results pose significant barriers. Bob describes the challenges in accessing effective treatments like vitamin K2, which, though available abroad, is restricted in the U.S. due to FDA regulations and pharmaceutical interests.
He recounts how they had to smuggle vitamin K3 from Japan and Italy for Kathy’s treatment, highlighting the difficulties faced by those without financial resources. Kathy, despite being given six weeks to live, remains in remission and healthy, thanks to these alternative treatments. Some doctors exposed to her case, including those at prestigious institutions like Sloan Kettering, are beginning to reconsider traditional methods, although resistance remains strong.
Art wraps up the conversation with Bob Guccione, expressing his interest in having another session to discuss cancer treatments further. Bob agrees, emphasizing the importance of spreading the message about alternative treatments and the ongoing fight against conventional cancer therapy methods. Art acknowledges the critical nature of their discussion, touching on life and death matters, and reiterates the value of every effort to raise awareness and help those affected. The show ends with Art thanking Bob and encouraging families affected by cancer to reach out.